ProPhase Labs Inc (PRPH) Company Profile & Statistics

ProPhase Labs Inc
PRPH
(Nasdaq - US)
Closed
0.77
-0.01 (-1.03%)
in:usd•As of: Nov 22, 2024 14:27 UTC -5
Open
0.80
High
0.80
Low
0.77

About ProPhase Labs Inc

CEO

Ted Karkus

Headquarters

711 stewart avenue, suite 200

garden city, ny 11530, united states

Auditor

Morison Cogen LLP

Employees

113

Share Holders

162

Website

www.prophaselabs.com

Industry

pharmaceuticals other

Sector

health technology

Company Overview

ProPhase Labs, Inc., formerly known as The Quigley Corporation, is a manufacturer, marketer and distributor of a diversified range of homeopathic and health products that are offered to the general public. The Company's mission is to develop and market natural health care pharmaceuticals and nutriceuticals that offer pioneering new options to improve patient treatment results. Its consumer health products, marketed through ProPhase Labs and certain subsidiaries, include the original COLD-EEZE?, a zinc gluconate glycine product. COLD-EEZE? family of lozenges and sugar free tablets reduce the severity and duration of the common cold. Its customers include wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. ProPhase Labs is also engaged in the research and development of potential natural base health products along with supplements and cosmeceuticals for human and veterinary use. The Company is headquartered in Doylestown, Pennsylvania.

ProPhase Labs Inc Statistics

Valuation Measures

Market Capitalization ²	18.35M
Enterprise Value	42.22M
Enterprise Value/EBITDA (ttm)	-1.60
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	0.38
Price to Sales (ttm)	1.42
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	-30.93%
Operating Margin (ttm)	-217.64%
Profit Margin (ttm)	-220.15%
Return on Equity (ttm)	-62.92%
Return on Invested Capital (ttm)	-46.49%
Return on Assets (ttm)	-30.22%

Income Statement

Revenue (ttm)	12.75M
Revenue Per Share (ttm)	0.53
Gross Profit (ttm)	-4.13M
EBITDA (ttm)³	-26.41M
Net Income Avi to Common (ttm)	-27.76M
Diluted EPS (ttm)	-1.26

Share Statistics

Beta (5Y Monthly)	-0.10
52-Week Change	-82.76%
S&P500 52-Week Change	31.00%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	23.87M
Dividend Yield	0.00%
Float ⁴	18.93M
% Held by Insiders	20.70%
% Held by Institutions	9.45%

Balance Sheet

Total Cash (mrq)	1.10M
Total Cash Per Share (mrq)	0.05
Total Debt (mrq)	24.96M
Total Debt/Equity (mrq)	65.47%
Current Ratio (mrq)	1.47%
Quick Ratio (mrq)	1.33%
Book Value Per Share (mrq)	2.00

Cash Flow

Operating Cash Flow Per Share (ytd)	-0.73
Free Cash Flow (ytd)	-14.88M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

ProPhase Labs Inc

Trade With A Regulated Broker